Skip to main content

Find Clinical Trials

Home
Conditions
Blasts 20-30 Percent of Bone Marrow Nucleated Cells

Clinical trial condition

Blasts 20-30 Percent of Bone Marrow Nucleated Cells

Explore clinical trials studying Blasts 20-30 Percent of Bone Marrow Nucleated Cells. Study availability and eligibility vary by location and protocol.

2 public trials 1 recruiting study

Refine in advanced search Browse all conditions

Blasts 20-30 Percent of Bone Marrow Nucleated Cells trial results

Recruiting

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

NCT03383575

Conditions: Acute Myeloid Leukemia, Anemia, Anemia, Refractory, +22 more
Locations: Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States

Cleveland Clinic Foundation Cleveland, Ohio, United States

M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

NCT03047993

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of Peripheral Blood White Cells, +18 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details